ImmunityBio, Inc.（纳斯达克代码：IBRX）宣布，其创新疗法Anktiva®（nogapendekin alfa inbakicept）联合卡介苗（BCG）已获得欧盟委员会批准，用于治疗非肌层浸润性膀胱癌（NMIBC）的原位癌（CIS）患者。此项授权标志着该疗法在欧洲经济区（EEA）的30个成员国以及冰岛、列支敦士登和挪威共33个国家获得上市许可，将显著提升全球患者对该前沿治疗方案的获取机会。
ImmunityBio, Inc.（纳斯达克代码：IBRX）宣布，其创新疗法Anktiva®（nogapendekin alfa inbakicept）联合卡介苗（BCG）已获得欧盟委员会批准，用于治疗非肌层浸润性膀胱癌（NMIBC）的原位癌（CIS）患者。此项授权标志着该疗法在欧洲经济区（EEA）的30个成员国以及冰岛、列支敦士登和挪威共33个国家获得上市许可，将显著提升全球患者对该前沿治疗方案的获取机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.